Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Merck ($MRK) scored a win as it received the European Union approval for its Keytruda drug. The approval allows the company to market the drug in all 28 EU member states plus Iceland, Lichtenstein, and Norway at the approved dose of 200 mg every three weeks. The approval was given based on the data from 241 patients from the Keynote-087 and Keynote-013 trials. Keytruda is designed for the  treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
Merck stock has shown strong movements as its price is now up 15 percent in the past 12 months. Its year to date gain stands at 7.66 percent. The stock is currently trading close to its 52 weeks high of $66.80.

Genomic Health Inc. ($GHDX) reported that a draft local coverage determination (LCD) for the Oncotype DX® Genomic Prostate Score™ has been issued by Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies.The draft LCD recommends Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer throughout the United States. 
Genomic Health has welcomed the decision and said that the positive draft local coverage determination is a positive step forward. The company stock has gained over 11 percent this year so far while its 12 months gain stands at 25 percent.

 

Johnson & Johnson ($JNJ) has been ordered to pay over $110 million in talc trial. The pharma company will have to pay a Virginia woman who claimed to have developed ovarian cancer after decades of using of its talc-based products for feminine hygiene. The Missouri jury verdict is the largest so far to arise out of about 2,400 lawsuits accusing J&J of not adequately warning consumers about cancer risks.
Regulus Therapeutics ($RGLS) announced the retirement of its President and CEO Paul Grint. He will be replaced  by COO Jay Hagan effective immediately. The company also promoted  VP of finance and accounting Daniel Chevallard to the position of CFO.

AbbVie ($ABBV) announced that it will present the data from 20 abstracts in gastroenterology and hepatology programs at Digestive Disease Week in Chicago. The research to be presented includes a Phase 2 study that evaluates the safety and efficacy of multiple dosing regimens of upadacitinib as induction therapy in patients with moderately to severely active Crohn's disease after 16 weeks of treatment.

 

VWR Corp ($CWR) has agreed to be acquired by Avantor for nearly $6.4 billion. Avantor is owned by Private Equity firm New Mountain Capital. VWR Corp is engaged in the business of Laboratory supplies. It has been offered $33.25 per share in cash, which represents 17% premium to the closing price on May 2, the day before the start of market speculation regarding a potential sale of VWR.
Windtree Therapeutics ($WINT) announced that it will delist from NASDAQ. The company stock will cease trading as  it no longer satisfies the listing requirement to maintain a minimum $2.5 million in stockholders' equity. The company plans to have its shares quoted on the OTC market beginning tomorrow under the WINT ticker.

 

TG Therapeutics Inc. ($TGTX) announced that it has incurred a loss of $27.7 million for the first quarter of the year. On per share basis, the quarterly loss stood at $0.52. The biopharmaceutical company posted revenue of $38,100 in the period. Its adjusted revenue was $38,000, matching Street forecasts.
ImmunoGen Inc. announced its first quarter loss at $17.3 million. The company said it had a loss of $0.20 per share. Its revenue for the quarter stood at $28.7 million. ImmunoGen expects full-year revenue in the range of $70 million to $75 million.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Barclays PLC
Reiterates
AMAG Pharmaceuticals (AMAG)
Hold
$25.00
Low
Needham & Company LLC
Reiterates
AtriCure (ATRC)
Buy
$25.00
Low
Maxim Group
Reiterates
bluebird bio (BLUE)
Hold

Low
Argus
Downgrades
Celgene (CELG)
Buy -> Hold

N/A
Aegis
Reiterates
Conatus Pharmaceuticals (CNAT)
Buy
$11.00
N/A
Cantor Fitzgerald
Reiterates
Computer Programs & Systems (CPSI)
Hold
$24.00
Low
William Blair
Upgrades
Catalent (CTLT)
Market Perform -> Outperform

N/A
Cowen and Company
Reiterates
Incyte (INCY)
Buy

Low

Gainers (% price change) Last Trade Change Mkt Cap
OraSure Tech., Inc. OSUR 15.64 +2.43 (18.40%) 901.86M
LHC Group, Inc. LHCG 60.96 +5.53 (9.98%) 1.11B
II-VI, Inc. IIVI 29.95 +2.23 (8.03%) 1.87B
Accelerate Diagnostics AXDX 29.25 +1.85 (6.75%) 1.51B
Regeneron Pharmaceuticals REGN 434.31 +27.28 (6.70%) 46.74B
Losers (% price change)
Cerus Corporation CERS 3.49 -0.75 (-17.69%) 353.89M
Masimo Corporation MASI 88.75 -14.73 (-14.23%) 4.57B
Progenics Pharmaceuticals PGNX 6.81 -1.01 (-12.92%) 471.60M
BioCryst Pharmaceuticals BCRX 5.78 -0.68 (-10.59%) 463.55M
IRIDEX Corporation IRIX 9.73 -0.81 (-7.69%) 107.44M
Most Actives (dollar volume)
Regeneron Pharmaceuticals REGN 434.31 +27.28 (6.70%) 46.74B
Pfizer Inc. PFE 33.45 -0.02 (-0.06%) 198.37B
Humana Inc HUM 228.85 +4.83 (2.16%) 32.79B
Gilead Sciences, Inc. GILD 68.08 +0.87 (1.29%) 87.21B
Merck & Co., Inc. MRK 63.38 -0.25 (-0.39%) 176.34B